Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.
2.

Repetitive Behavioral Assessments for Compound Screening in Mouse Models of Autism Spectrum Disorders.

Rizzo SJ.

Methods Mol Biol. 2016;1438:293-310. doi: 10.1007/978-1-4939-3661-8_17.

PMID:
27150097
3.

Future viable models of psychiatry drug discovery in pharma.

Rizzo SJ, Edgerton JR, Hughes ZA, Brandon NJ.

J Biomol Screen. 2013 Jun;18(5):509-21. doi: 10.1177/1087057113475871. Epub 2013 Feb 7. Review.

PMID:
23392517
4.

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.

Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN.

Sci Transl Med. 2012 Apr 25;4(131):131ra51. doi: 10.1126/scitranslmed.3003501.

5.

3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.

Gilbert AM, Bursavich MG, Lombardi S, Adedoyin A, Dwyer JM, Hughes Z, Kern JC, Khawaja X, Rosenzweig-Lipson S, Moore WJ, Neal SJ, Olsen M, Rizzo SJ, Springer D.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):195-9. doi: 10.1016/j.bmcl.2010.11.038. Epub 2010 Nov 12.

PMID:
21126874
6.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, Wantuch C, Zhang MY, Cummons T, Leventhal L, Bender CN, Zhang J, Kowal D, Lu S, Rajarao SJ, Smith DL, Shilling AD, Wang J, Butera J, Resnick L, Rosenzweig-Lipson S, Schechter LE, Beyer CE.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1193-205. doi: 10.1017/S1461145709991088. Epub 2010 Jan 5.

7.

Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models.

Dwyer JM, Rizzo SJ, Neal SJ, Lin Q, Jow F, Arias RL, Rosenzweig-Lipson S, Dunlop J, Beyer CE.

Psychopharmacology (Berl). 2009 Mar;203(1):41-52. doi: 10.1007/s00213-008-1373-7. Epub 2008 Oct 24.

PMID:
18949460
8.

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).

Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE.

J Pharmacol Exp Ther. 2008 Apr;325(1):134-45. doi: 10.1124/jpet.107.133082. Epub 2008 Jan 8.

PMID:
18182558
9.

Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects.

Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S.

Neuropsychopharmacology. 2007 Nov;32(11):2360-8. Epub 2007 Mar 7.

Supplemental Content

Loading ...
Support Center